]>
IRCT20170325033132N3 IRCT 2018-02-18 Astra Zeneca The nebulized Budezonide (pulmicort) effectiveness in acute adult asthma attack Comparison of the effectiveness of nebulized Budezonide (pulmicort) versus placebo in the treatment of adult with moderate to severe acute asthma referring to Dr Shariati and Sina hospitals from 2017 to 2018 2016-03-20 anticipated 40 Complete https://irct.ir/trial/28446 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: random no. 4 blocks, Blinding description: There is a closed pocket for drug or placebo in the hand of triage nurse and randomly she/he give the pocket to the patients. Both of the patient and doctor don't know about drug/placebo but triage nurse alert about the drug or placebo which specify to any patient. Drug/placebo in the same form with the same dose injected to the patient. 2-3 asthma. Intervention 1: Intervention group: patients with acute asthma, nebulized budezonide(pulmicort) will be administered with the dose of 0.5 mg every half an hour up to three dose in additional standard treatment of asthma. Intervention 2: Control group: patients with acute asthma, nebulized normal salin (placebo). Yes - There is a plan to make this available What will be shared: all of the data after hiding personal information When: 6 months after publishing To whom: researchers in universities Conditions: everybody who access the open access journals Where to obtain: Dr Elnaz VAhidi Dr Maryam Habibi Samadi Dr Shariati hospital, North karegar, jalalealeahmad How to obtain: supplemental file Comments:
public maryam habibi samadi
Dr shariati Hospital, North Karegar, Jalal Aleahmad
tehran Iran (Islamic Republic of) 1411713135 +98 21 84901 maryamhabibi2011@yahoo.com Tehran University of Medical Sciences scientific Elnaz Vahidi
Dr shariat hospital, North karegar,
تهران Iran (Islamic Republic of) 1411713135 +98 21 84901 evahidi62@yahoo.com Tehran University of Medical Sciences Iran (Islamic Republic of) Age > 18 with signed informed consent letter Patients with acute asthma(moderate to severe) 18 years no limit Both Unwillingness of patients to participate in the study Patients with COPD Pneumonia Pneumothorax CHF Acute and severe respiratory failure with cyanosis and confusion Loss of consciousness Pregnant patients Smokers Intubated patients and patients with unstable vital signs New case of asthma Hemodynamic instability J45.51 Severe persistent asthma with (acute) exacerbation Treatment - Drugs Placebo Intervention group: patients with acute asthma, nebulized budezonide(pulmicort) will be administered with the dose of 0.5 mg every half an hour up to three dose in additional standard treatment of asthma Control group: patients with acute asthma, nebulized normal salin (placebo) Improvement of vital sign and clinical symptoms in patients with asthma attack. Timepoint: At the begining of the study(before intervention), 30, 60, 180 minutes after treatment. Method of measurement: physical exam. Relief of acute asthma attack(sign and symptom)from patient and dr "view. Timepoint: During the treatment in emergency center. Method of measurement: by completing questionnaire form, follow up, ask question about the number of readmission rate and length of hospitalization. Astra Zeneca Approved 2016-10-25 Ethics committee of Tehran university of medical sciences Tehran university of medical sciences , Qods St, Keshavarz Blvd, Tehran, Iran Tehran Tehran Iran (Islamic Republic of)